Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Reverse Merger Complete, Transcept Looks To Partner Intermezzo

This article was originally published in The Pink Sheet Daily

Executive Summary

Newly public specialty firm anticipates annual U.S. sales of $600 million for middle-of-night sleep aid.
Advertisement

Related Content

Financings Of The Fortnight: Biotech IPO Trends Continue With Supernus’ Offering – Haircuts, Insider Buys
Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
Reacting to the Crisis: Biotech Venture Capital's Plan B
Shell Game: Difficult Time For Reverse Mergers
Novacea/Transcept Reverse Merger To Fund Intermezzo Sleep Aid Launch
Schering-Plough Backs Out Of Asentar Agreement With Novacea
Schering-Plough Backs Out Of Asentar Agreement With Novacea

Topics

Advertisement
UsernamePublicRestriction

Register

PS068974

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel